This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Merit Medical Systems Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Merit Medical Systems has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
Merit Medical (MMSI) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Merit Medical (MMSI) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.
XRAY or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. MMSI: Which Stock Is the Better Value Option?
Merit Medical (MMSI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical (MMSI) Up 5.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 6.67% and 1.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Investors Should Bet on Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.
Top Ranked Growth Stocks to Buy for March 7th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 7th
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson's (BDX) MAX enteric viral panel receives FDA clearance.
DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors
by Zacks Equity Research
DENTSPLY (XRAY) expects to see solid performance in Europe and the rest of the world.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Buoyed by a strong first quarter, Varian Medical (VAR) has kept its fiscal 2019 guidance intact.
Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) registers solid expansion in adjusted gross margins in fourth-quarter 2018.
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Amedysis, Southwest Airlines and Royal Caribbean
by Zacks Equity Research
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Amedysis, Southwest Airlines and Royal Caribbean
Worried About Rate Hikes? Buy These 5 Low Leverage Stocks
by Zacks Equity Research
If a company is highly leveraged, investors will not add it to their portfolios. A high degree of financial leverage means high interest payments, which may affect a company's bottom line.
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Steelcase, Southwest and EMCOR
by Zacks Equity Research
Zacks.com featured highlights include: Merit Medical, Pinnacle West, Steelcase, Southwest and EMCOR
Bet on These 5 Low Leverage Stocks to Escape Debt Traps
by Zacks Equity Research
With the Q4 earnings season in full swing currently, investors must be targeting companies with solid earnings growth projections. But they must consider their debt level first.
3 Reasons Growth Investors Will Love Merit Medical (MMSI)
by Zacks Equity Research
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Top Ranked Growth Stocks to Buy for January 15th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 15th
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace